Wednesday, March 29, 2023


Biotechnology News Magazine


Variantyx Secures $20M in Funding

The series C funding round was led by GHS Fund (Quark Venture LP and GF Securities) and includes new investor, IBM Ventures and current investors, Pitango Venture Capital, New Era Capital Partners, 20/20 HealthCare Partners. Zafrira Avnur, PhD, Quark Venture Chief Scientific Officer & Partner, will join the Variantyx board of directors.

OnKure Raises $55 Million Series B Funding

Proceeds will be used to advance the Company’s next generation histone deacetylase (HDAC) inhibitors further into clinical development and fund a growing pipeline of earlier stage molecules.

YishengBio Raises $130 Million in Series B Funding

This round of funding will strongly support the expansion of the company's R&D center, accelerate their commercialization strategies including the clinical development of multiple vaccine candidates, and the construction of biologics production facilities in China and Singapore.

Electromedical Technologies Secures $1Mil for Product Expansion

The company secured a $1 million investment by a fund managed by Yorkville Advisors Global, LP to complete prototype production of its WellnessPlus POD

Teon Therapeutics Completes $30 Million Series A Financing

Financing was led by Oceanpine Capital with participation from additional new investors Oriza Ventures, Lifespan Investments, and former Gilead senior executives.

Sciwind Biosciences Secures US$37 Million Series B Financing

Sciwind Biosciences notes financing was led by LYFE Capital and joined by the existing investors, Legend Capital and Haibang Venture Capital.